Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ–stimulated antitumor immunity
Jiale Ren, … , Moubin Lin, Jun Qin
Jiale Ren, … , Moubin Lin, Jun Qin
Published March 1, 2022
Citation Information: J Clin Invest. 2022;132(8):e153167. https://doi.org/10.1172/JCI153167.
View: Text | PDF
Research Article Oncology

Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ–stimulated antitumor immunity

  • Text
  • PDF
Abstract

IFN-γ–stimulated MHC class I (MHC-I) antigen presentation underlies the core of antitumor immunity. However, sustained IFN-γ signaling also enhances the programmed death ligand 1 (PD-L1) checkpoint pathway to dampen antitumor immunity. It remains unclear how these opposing effects of IFN-γ are regulated. Here, we report that loss of the histone dimethyltransferase WHSC1 impaired the antitumor effect of IFN-γ signaling by transcriptional downregulation of the MHC-I machinery without affecting PD-L1 expression in colorectal cancer (CRC) cells. Whsc1 loss promoted tumorigenesis via a non-cell-autonomous mechanism in an Apcmin/+ mouse model, CRC organoids, and xenografts. Mechanistically, we found that the IFN-γ/STAT1 signaling axis stimulated WHSC1 expression and, in turn, that WHSC1 directly interacted with NLRC5 to promote MHC-I gene expression, but not that of PD-L1. Concordantly, silencing Whsc1 diminished MHC-I levels, impaired antitumor immunity, and blunted the effect of immune checkpoint blockade. Patient cohort analysis revealed that WHSC1 expression positively correlated with enhanced MHC-I expression, tumor-infiltrating T cells, and favorable disease outcomes. Together, our findings establish a tumor-suppressive function of WHSC1 that relays IFN-γ signaling to promote antigen presentation on CRC cells and provide a rationale for boosting WHSC1 activity in immunotherapy.

Authors

Jiale Ren, Ni Li, Siyu Pei, Yannan Lian, Li Li, Yuchong Peng, Qiuli Liu, Jiacheng Guo, Xuege Wang, Ying Han, Guoying Zhang, Hanling Wang, Yaqi Li, Jun Jiang, Qintong Li, Minjia Tan, Junjie Peng, Guohong Hu, Yichuan Xiao, Xiong Li, Moubin Lin, Jun Qin

×

Figure 4

Whsc1 KO induces resistance to antitumor immunity via MHC-I expression.

Options: View larger image (or click on image) Download as PowerPoint

Whsc1 KO induces resistance to antitumor immunity via MHC-I expression....
(A) Effects of Whsc1 loss on CT26 cell–derived (BALB/c) and MC38 cell–derived (C57BL/6 or Rag1–/–) tumor growth (n = 6). (B) Representative luminescence images of cecum xenografts derived from KAP organoids in C57BL/6 or Nude mice after 30 days of injections. (C) Luminescence quantification of cecum xenografts (n = 8). Luc, luciferase. (D) H&E staining of the cecum sections. Scale bars: 200 μm. (E) Flow cytometric analysis of CD8+ T cells, CD4+ T cells, and macrophages in tumors (n = 5–8). (F) Flow cytometric analysis of GZMB+ and IFN-γ+CD8+ T cells (n = 8). (G) Coculturing of OT-1 cells with MC38-OVA. After 48 hours, the viability of MC38-OVA cells was analyzed by flow cytometry (n = 4). Effector to target (E/T) ratios are shown. (H) ELISA assay for T cell effector cytokines following 48 hours of coculturing with MC38-OVA cells (n = 3). (I) Tumor growth in BALB/c mice subcutaneously injected with CT26 cells (n = 6). Scale bar: 1.5 cm. (J) Percentages of CD8+ T cells in tumors (n = 4). The numbers within the quadrants of the plot indicate the percentage of CD8+ T cells among total CD45+ cells. (K) CT26 tumor growth in BALB/c mice treated with anti-CD8 antibody or isotype. The mice were treated every 3 days immediately after tumor cell inoculation (n = 6). Scale bar: 1.5 cm. (L) CT26 subcutaneous tumor growth in BALB/c mice treated with anti–PD-1 antibody or isotype control antibody (n = 6). The mice were treated every 3 days after 8 days of tumor cell implantations. Data are presented as the mean ± SEM. *P < 0.05 and **P < 0.01, by 2-way ANOVA followed by multiple comparisons (A and H–L) and 2-tailed Student’s t test (C and E–G) .

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts